HIGH RISK MYELODYSPLASTIC SYNDROME
Clinical trials for HIGH RISK MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new HIGH RISK MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for HIGH RISK MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody takes aim at Hard-to-Treat blood cancers
Disease control OngoingThis early-stage study tests a new antibody drug called Hu8F4 in 72 people with advanced blood cancers like leukemia and myelodysplastic syndrome. The main goals are to find the safest dose and check for side effects. The drug works by targeting a protein on cancer cells to stop …
Matched conditions: HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
Precision radiation may make stem cell transplants safer for blood cancer patients
Disease control OngoingThis study tests a new way to deliver radiation before a stem cell transplant for people with leukemia or myelodysplastic syndrome (MDS). Instead of radiating the whole body, the new method (TMLI) targets only the bone marrow and lymph nodes, which may reduce damage to healthy or…
Matched conditions: HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New transplant timing strategy may tame High-Risk blood cancers
Disease control OngoingThis study tests a specific schedule of chemotherapy drugs (busulfan and fludarabine) followed by a donor stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. After the transplant, a drug called cyclophosphamide is given to help prevent the don…
Matched conditions: HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
New combo therapy shows promise for tough blood cancers
Disease control OngoingThis study tests a combination of two chemotherapy drugs (CPX-351) plus a targeted antibody (gemtuzumab ozogamicin) in about 50 adults whose acute myeloid leukemia or high-risk myelodysplastic syndrome has returned or not responded to prior treatment. The goal is to see if the co…
Matched conditions: HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 08, 2026 12:03 UTC